In this context, the well‐known anti‐protozoal drug pentamidine17 has been shown to disrupt S100B‐wtp53 interaction in melanoma and glioma cells, acting as an inhibitor of S100B pro‐cancerogenic activity.8, 18, 19 This evidence has clinically translated into ongoing clinical trials, aiming at testing the efficacy of pentamidine as an anticancer drug, in melanoma patients and in patients with metastatic colon cancer undergoing standard chemotherapy as second‐line and/or third‐line treatment (ClinicalTrials.gov Identifier: NCT00729807 and NCT00809796, respectively). This evidence concerns the gene S100B and melanoma.